Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties

mAbs

Volumn 9, Issue 2, 2017, Pages 240-256

  Bezabeh, Binyam ^a   Fleming, Ryan ^a   Fazenbaker, Christine ^b   Zhong, Haihong ^b   Coffman, Karen ^c   Yu, Xiang Qing ^c   Leow, Ching Ching ^c   Gibson, Nerea ^a   Wilson, Susan ^a   Stover, C Kendall ^d   Wu, Herren ^a   Gao, Changshou ^a   Dimasi, Nazzareno ^a  

^a Antibody Discovery and Protein Engineering   (United States)

^b Oncology Research   (United States)

^c Clinical Pharmacology and DMPK   (United States)

^d MedImmune   (United States)

Author keywords

Antibody engineering; bispecific antibody; concurrent binding to antigens; multispecific antibody; single chain antibody Fv; tetravalent antibody

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; BISPECIFIC ANTIBODY; CYSTEINE; FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VANUCIZUMAB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; ANGPT2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY ISOELECTRIC FOCUSING; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HALF LIFE TIME; HINGE REGION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIZE EXCLUSION CHROMATOGRAPHY; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL TUMOR; DRUG SCREENING; PROCEDURES; PROTEIN ENGINEERING;

ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOGLOBULIN G; MICE; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011320159     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1270492     Document Type: Article

References (37)

1. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393(3):672-92; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
2. Dimasi N, Fleming R, Hay C, Woods R, Xu L, Wu H, Gao C. Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells. Mol Pharm 2015; 12(9):3490-501; PMID:26176328; http://dx.doi.org/10.1021/acs.molpharmaceut.5b00268
3. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mole Immunol 2015; 67(2 PtA):95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
4. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15(2):159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159
5. Wu C. Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25(11):1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
6. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16(7):677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
7. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31(8):753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
8. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323(5921):1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
9. Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs 2017; PMID:28071970; http://dx.doi.org/10.1080/19420862.2016.1268307
10. Karnell JL, Dimasi N, Karnell FG, 3rd, Fleming R, Kuta E, Wilson M, Wu H, Gao C, Herbst R, Ettinger R. CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol 2014; 192(4):1480-90; PMID:24442430; http://dx.doi.org/10.4049/jimmunol.1301361
11. Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov 2014; 13(11):799-801; PMID:25359367; http://dx.doi.org/10.1038/nrd4478
12. Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today 2015; 20(5):588-94; PMID:25757598; http://dx.doi.org/10.1016/j.drudis.2015.02.013
13. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014; 6(262):262ra155; PMID:25391481; http://dx.doi.org/10.1126/scitranslmed.3009655
14. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70(6):2213-2223; PMID:20197469; http://dx.doi.org/10.1158/0008-5472.CAN-09-1977
15. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 2013; 19(24):6730-40; PMID:24097868; http://dx.doi.org/10.1158/1078-0432.CCR-13-0081
16. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiolog Rev 2011; 91(3):1071-121; PMID:21742796; http://dx.doi.org/10.1152/physrev.00038.2010
17. Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, et al. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. Mabs 2016; 8(3):562-73; PMID:26864324; http://dx.doi.org/10.1080/19420862.2016.1147640
18. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The Covalent Structure of an entire γG immunoglobulin molecule. Proc Natl Acad Sci. USA 1969; 63(1):78-85; PMID:5257969; http://dx.doi.org/10.1073/pnas.63.1.78
19. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V, Allen G. Specific cleavage of immunoglobulin G by copper ions. Int J Pept Protein Res 1996; 48(1):48-55; PMID:8844262; http://dx.doi.org/10.1111/j.1399-3011.1996.tb01105.x
20. Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. MAbs 2011; 3(3):253-63; PMID:21487244; http://dx.doi.org/10.4161/mabs.3.3.15608
21. Glover ZK, Basa L, Moore B, Laurence JS, Sreedhara A. Metal ion interactions with mAbs:Part 1. MAbs 2015; 7(5):901-11; PMID:26121230; http://dx.doi.org/10.1080/19420862.2015.1062193
22. Jung SH, Pastan I, Lee B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins 1994; 19(1):35-47; PMID:8066084; http://dx.doi.org/10.1002/prot.340190106
23. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438(7070):967-74; PMID:16355214; http://dx.doi.org/10.1038/nature04483
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347):298-307; PMID:21593862; http://dx.doi.org/10.1038/nature10144
25. Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012; 118(14):3455-67; PMID:22086782; http://dx.doi.org/10.1002/cncr.26540
26. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 2014; 8(3):696-706; PMID:25088418; http://dx.doi.org/10.1016/j.celrep.2014.06.059
27. Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One 2013; 8(2):e54923; PMID:23405099; http://dx.doi.org/10.1371/journal.pone.0054923
28. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333(2):328-35; PMID:15961063; http://dx.doi.org/10.1016/j.bbrc.2005.05.132
29. Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, et al. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. MAbs 2016; 8(3):562-73; PMID:26864324; http://dx.doi.org/10.1080/19420862.2016.1147640
30. Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua W.F. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008; 45(7):1872-82; PMID:18078997; http://dx.doi.org/10.1016/j.molimm.2007.10.042
31. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64(Pt 6):700-4; PMID:18560159; http://dx.doi.org/10.1107/S0907444908007877
32. Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn:The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol 2015; 194(10):4595-603; PMID:25934922; http://dx.doi.org/10.4049/jimmunol.1403014
33. Monnet C, Jorieux S, Urbain R, Fournier N, Bouayadi K, De Romeuf C, Behrens CK, Fontayne A, Mondon P. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis:impact on effector functions. Front Immunol 2015; 6:39; PMID:25699055; http://dx.doi.org/10.3389/fimmu.2015.00039
34. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33):2314-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
35. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46(8–9):1750-5; PMID:19250681; http://dx.doi.org/10.1016/j.molimm.2009.01.026
36. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012; 40(5):1321-30; PMID:22327175; http://dx.doi.org/10.3892/ijo.2012.1366
37. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9(1):145-56; PMID:20053776; http://dx.doi.org/10.1158/1535-7163.MCT-09-0554